We chat with Tesla La Touche who is the Founder and CEO of Aphrodite Health, the first ever female-founded biotech company within the medicinal psychedelic industry.
Similar Posts
Psilocybin Trial Treating Depression CRUSHES It [Are We At A Turning Point?]
Results Are OUT! Finally we see that psilocybin is MORE EFFECTIVE in treating depression than the commonly used SSRIS. This study, run by the Imperial College of London is the FIRST MAJOR STUDY directly comparing SSRI’s with psilocybin, the predominant method of treatment.
The data was released on the 14th of April. So yes, this psilocybin trial treating depression CRUSHED SSRIS!
The study had 59 patients with Major Depressive Disorder, 30 of whom took 2 doses of Psilocybin 3 weeks apart, and 29 of whom took an SSRI, and the results will have MASSIVE IMPLICATIONS throughout the psychedelic investing world.
Though the study’s primary research objective which was purely by how much depression declined using the Quids SR 16 test, EVERY OTHER MEASUREMENT, such as using other measuring methods, decreases in Suicide ideation and percentage of patients in remission were secondary research objectives.
And again, every secondary research objective heavily FAVORED psilocybin.
This will be major news for companies like Compass Pathways (CMPS) and MindMed (MMED / MMEDF / MMQ)
Link to study: https://www.nejm.org/doi/suppl/10.1056/NEJMoa2032994/suppl_file/nejmoa2032994_appendix.pdf
So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
…
https://benzinga.grsm.io/thepsychedel
…
General thoughts. We’ve been covering decriminalization and legalization efforts for almost two months now and EVERY WEEK, we see a new state or city starting to understand that psychedelics may be beneficial to society and may be able to treat mental illnesses such as depression, anxiety, ADHD, etc. On top of that, every week, we see study after study releasing promising results on the benefits of psychedelics to treat such mental maladies. If this is not proof that the SHROOM BOOM is real, what is? As more studies are released, it’ll only become more clear that psychedelics such as psilocybin, MDMA, DMT, LSD, etc may be able to disrupt a TRILLION dollar industry and us psychedelic investors might as well extract two-fold benefits : a. getting massive returns on investment and b. contributing to make the world a better place.
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #psilocybin #shroomboom
Moms on Mushrooms – Bringing Moms Together Through Microdosing with Tracey Tee
Moms On Mushrooms empowering a community of moms to learn about the value of building a relationship with mushrooms and to support each other in their microdosing journeys.
This Week in Psychedelic Stocks [UPDATES ON MINDMED (MMED/MMEDF/MMQ) CMPS, MYCOF, NUMI & ATAI, TRIP]
In today’s episode of “This Week in Psychedelic Stocks”, we’ll see some news on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Atai Life Sciences, Mydecine (MYCO/MYCOF), Numinuss Wellness (NUMI), and Red Light Holland (TRIP).
We will cover the latest developments in the field writ large.
This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.
Time Stamps
0:00 – Intro
0:35 – Imperial College Of London results of Study the effects of microdosing psychedelics and their impact on the psychedelic industry
5:45 – 15 Canadian healthcare professionals begin a historic psilocybin training program
6:55 – Chief of the Defense Force, Chris Barrie, is calling for psychedelic compounds like psilocybin and MDMA to be rescheduled
8:31 – A smartphone app called promises to induce a psychedelic like state (FUN)!
10:58 – MindMmed Stock News ( MMED/MMEDF/MMQ) and Company Updates
13:33 – Compass Pathways (CMPS) Stock News and Company Updates
15:22 – Atai Life Sciences Company News and IPO Speculation
16:42 – Numinus (NUMI) Stock News & 3 Company Updates
19:30 -Red Light Holland (TRIP) Stock News & Very Interesting Company Update
20:52 – Mydecine (MYCO/MYCOF) Stock News & Updates
So this is it for This Week in Psychedelic Stocks fellow psychedelic investors!
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #PsychedelicStocks
How Risky is MindMed Stock? (MMED / MMEDF Risk Assessment)
Today, we have a different episode for you..Usually we talk about all the things I am excited for when it comes to MindMed and MindMed stock, but today, we will visit the darker side by discussing how risky is the MindMed stock.
It is important for all psychedelic investors to grasp that MindMed is not a sure deal. Yes, I believe that long term it will succeed, but there are certain things that could go wrong.
We will cover the very real risks involved in investing in MindMed such as:
1. The possibility of MindMed’s medicines being inefficacious
– Whether of not MMED’s clinical trials succeed
2.MindMed’s incertain long term profitability
– Can the company scale production and training protocols?
3.MindMed Stock volatility
– MindMed’s market cap
– Future short interests
MindMed trades on the Canadian NEO Market as (MMED) and American OTC market as (MMEDF)
MindMed is the leader in psychedelic medicines, and is my top Psychedelic Stock. Is MindMed a buy? Is MindMed a good Investment? Watch our channel to find out!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://mindmed.co/wp-content/uploads/2020/11/end-of-year-2019-discussion.pdf
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own
The Mainstream Media GETS Psychedelic Stocks [Like MMEDF, CMPS, EHVVF & FTRPF]
Hello psychedelic investors! Today’s episode will be a little different. We will discuss the recent media coverage of psychedelic stocks and its role in psychedelic inspired companies’ future.
It appears that the mainstream media understands the potential for psychedelic stocks to disrupt the pharmaceutical Industry. Now understanding what this means, and its implications is extremely important for retail investors like you and me.
We’ll also zoom into one piece of media about MindMed (MMED/MMEDF) and Compass Pathways (CMPS), and explore how it hits the nail on the head.
We are going to do this because one, it’s a good article that I wanted to share with you
And two, it exemplifies my point that the mainstream understands the potential here, and might actually be on the right side of history.
P.S. I mention in the video that the article I’m discussing is by Yahoo Finance. It turns out the article is from OTC stock review.
For those interested in reading the entire article: https://ca.movies.yahoo.com/264-million-reasons-psychedelic-stocks-133000885.html
Time Stamps
0:00 – Intro
3:10 – Media Coverage on Tesla & Psychedelic Stocks
6:36 – Benefits of the media covering Psychedelic Companies like (MMEDF & CMPS)
8:05 – Influence on stock valuations and stealth investors
10:57 – 264 Million Reasons Why Psychedelic Stocks Have More Room To Grow
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #PsychedelicStocks
Interview With Joël Brierre
In this episode of the Psychedelic Spotlight podcast we speak with Joël Brierre who is the founder & CEO of Kaivalya Kollectiv.